TD Private Client Wealth LLC Has $158,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

TD Private Client Wealth LLC trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 36.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,137 shares of the medical research company’s stock after selling 1,209 shares during the period. TD Private Client Wealth LLC’s holdings in Edwards Lifesciences were worth $158,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in EW. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the 4th quarter worth about $30,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $30,000. Avior Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $54,000. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Citigroup raised their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $71.29 on Wednesday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $41.91 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.12. The company has a 50-day simple moving average of $71.43 and a 200 day simple moving average of $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,303 shares of company stock valued at $3,715,776 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.